Table of Contents 2
List of Tables 4
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Melanoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Melanoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Melanoma Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Melanoma 30
Dec 13, 2017: Enrollment of First Patient in Investigator-Initiated Clinical Trial for Telomelysin (OBP-301) - pembrolizumab combination therapy 30
Dec 11, 2017: Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews 30
Dec 08, 2017: Novel Compound Restores Immune Response In Patients With Melanoma 30
Dec 05, 2017: Moleculin’s WP1066 Drug gets FDA Brain Tumor IND Clearance 31
Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial 31
Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting 32
Nov 11, 2017: First Data for NKTR-214 in Combination with OPDIVO (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 32
Nov 10, 2017: X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO 34
Nov 07, 2017: Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting 34
Nov 03, 2017: Adaptimmune to Present Update On MAGE-A4 Multi-tumor Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting 35
Nov 03, 2017: First Clinical Data from Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer Annual Meeting 35
Oct 30, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics 36
Oct 30, 2017: Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute 36
Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma 36
Clinical Trial Profile Snapshots 38
Appendix 1299
Abbreviations 1299
Definitions 1299
Research Methodology 1300
Secondary Research 1300
About GlobalData 1301
Contact Us 1301
Disclaimer 1301
Source 1302

List of Tables
Melanoma Therapeutics, Global, Clinical Trials by Region, 2017* 7
Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
Melanoma Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
Proportion of Melanoma to Oncology Clinical Trials, G7 Countries (%), 2017* 15
Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Melanoma to Oncology Clinical Trials, E7 Countries (%), 2017* 18
Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Melanoma Therapeutics, Global, Clinical Trials by Phase, 2017* 21
Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29

List of Figures
Melanoma Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
Melanoma Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 13
Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14
Proportion of Melanoma to Oncology Clinical Trials, G7 Countries (%), 2017* 15
Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Melanoma to Oncology Clinical Trials, E7 Countries (%), 2017* 18
Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Melanoma Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
GlobalData Methodology 1300

Companies Mentioned
- Bristol-Myers Squibb Co
- F. Hoffmann-La Roche Ltd
- Merck & Co Inc
- Novartis AG
- GlaxoSmithKline Plc
- AstraZeneca Plc
- Pfizer Inc
- Sarah Cannon Research Institute LLC
- Eisai Co Ltd
- Amgen Inc